InMed Pharmaceuticals (INM) Total Current Liabilities (2020 - 2026)

InMed Pharmaceuticals' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 20.25% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $2.2 million, a 20.25% increase from a year earlier, with the FY2025 full-year figure at $1.8 million, down 6.7% from the prior year.
• Total Current Liabilities advanced to $2.2 million in Q1 2026 per INM's latest filing, from $1.5 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $4.1 million in Q1 2022 and bottomed at $1.3 million in Q3 2023.
• The 5-year median for Total Current Liabilities is $1.8 million (2025), against an average of $2.1 million.
• Across the five-year window, Total Current Liabilities soared 139.49% in 2022 and plunged 59.19% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $2.4 million in 2022, then sank by 30.0% to $1.7 million in 2023, then advanced by 6.57% to $1.8 million in 2024, then slipped by 17.36% to $1.5 million in 2025, then soared by 49.41% to $2.2 million in 2026.
• Per Business Quant, the three latest INM Total Current Liabilities figures stand at $2.2 million (Q1 2026), $1.5 million (Q4 2025), and $1.6 million (Q3 2025).